In non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology recommend biomarker testing be performed using broad NGS panels to detect druggable rearrangements or fusions involving ALK, NTRK, ROS1, and RET with consideration of RNA sequencing if not previously performed (Ettinger et al., 2022). This evidence concerns the gene RET and non-small cell lung carcinoma.